Cerus Corporation (NASDAQ:CERS) announced today its schedule of key events at the AABB (formerly known as the American Association of Blood Banks) Annual Meeting to be held October 7-10 in San Diego, California. Cerus will be presenting the latest clinical data while blood banks and hospitals will be publishing results from their own user experience.
Company representatives from Cerus will also be in the exhibition area at booth 1910.
The AABB Annual Meeting is the largest blood banking conference of the year globally and scientists and clinicians from around the world will be attending to hear the latest developments in the industry.
“We are looking forward to AABB and sharing with the blood banking community the latest clinical data supporting the use of INTERCEPT to treat blood components,” said Dr. Richard Benjamin, Cerus’ chief medical officer.
“Between Cerus and our scientific collaborators, we will have 19 abstract presentations including three oral abstracts. The abstracts this year cover a broad spectrum of topics including platelets, plasma, red blood cells, whole blood, and emerging pathogens.
In addition, this year at AABB, we will have our first presentation related to our cryoprecipitate initiative. The abstract shows that pathogen reduced cryo can be processed from various plasma sources and can be stored at room temperature for 5 days,” Benjamin continued.
A full list of abstracts can be viewed at https://intercept-usa.com/aabb17.
SCHEDULE OF SESSIONS OF INTEREST (listed chronologically): |
| Sunday, October 8 |
| 2:00 - 3:30 pm - 0224-S TTD II-Pathogen Reduced Platelets: Implementation Considerations, Convention Center - 20A |
| Monday, October 9 |
| 2:00 – 2:15 pm – C43-A03F: Compatibility of Apheresis Platelet Collections with Pathogen Reduction While Maintaining Current Split Rates, Convention Center – 29A |
| 5:15 – 5:30 pm – C60-A03J: Robust Inactivation of Mayaro Virus in Platelet Concentrates and Red Blood Cells Using Nucleic Acid Targeting Pathogen Reduction Technologies (PRT), Convention Center - 25AB |
| Tuesday, October 10 |
7:00 – 8:15 am – Cerus Presents “Experiences in Implementing Pathogen Reduction – From Maintaining Split Rates at the Blood Center to Treating Patients at the Hospital, Convention Center – 29A |
| 2:30 – 2:45 pm – C92-A04C: Hemovigilance Monitoring of Platelet Septic Transfusion Reactions (STR) after Treatment with INTERCEPTTM Pathogen Reduction or Large Volume, Delayed Bact/ALERTTM Bacterial Culture Screening, Convention Center – 30ABC |
ABOUT CERUS
Cerus Corporation is a biomedical products company focused in the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. The nucleic acid targeting mechanism of action of the INTERCEPT treatment is designed to inactivate established transfusion threats, such as hepatitis B and C, HIV, West Nile virus and bacteria, as well as emerging pathogens such as chikungunya, malaria and dengue. Cerus currently markets and sells the INTERCEPT Blood System for both platelets and plasma in the United States, Europe, the Commonwealth of Independent States, the Middle East and selected countries in other regions around the world. The INTERCEPT Red Blood Cell system is in clinical development. See http://www.cerus.com for information about Cerus.
INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171002005354/en/
Contacts:
Cerus Corporation
Tim Lee, 925-288-6137
Investor
Relations Director
or
Media Contact:
W20 Communications
Dan
Boyle
dan@boylepr.com
